

PRESS RELEASE

October 10, 2025

Oral presentation at the American College of Rheumatology on CR10049, the first intra-articular, long-acting Src family kinase inhibitor for the inflammatory osteoarthritis (OA) phenotype

Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that preclinical data supporting the advancement of CR10049 will be presented in an oral presentation at the upcoming American College of Rheumatology (ACR) world's premier rheumatology congress, to be held October 24 – 29, 2025 in Chicago, Illinois.

Presentation Details

Session: Osteoarthritis & Joint Biology – Basic Science

Abstract Title: CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype.

Abstract Number: 1737

Presenting Author: Luigi Giancotti

Presentation Session Date and Time: Tuesday, October 28, 2025, 10:45 AM - 11:00 AM CT

The abstract is available online [here](#). Data presented at the congress will be available to view in this website page after the end of the congress.

CR10049 (kinase inhibitor for the inflammatory OA phenotype)

CR10049 is a potent and long-acting OA-targeted multi-kinase inhibitor, preferentially targeting SRC family members, that plays a role in both OA pain (symptom-modifying) and inflammatory joint degeneration (structure-modifying). One such drug would be a major breakthrough in the treatment of the inflammatory OA phenotype.

About Rottapharm Biotech

Rottapharm Biotech is a research company dedicated to the discovery and development of innovative drugs, located in Monza (Italy). The company expertise in research and development includes medicinal/computational chemistry for small molecules, development of biologics and advanced therapies, new targets validation, pharmacological and pharmacokinetic characterization of new drug candidates, original formulations, and design of innovative clinical trials. The company strategy is to develop its own pipeline independently and then seek partnerships with pharmaceutical companies, as well as investing in alliances on innovative projects of other biotech companies or university spin-offs.

Contact

Federica Girolami, Business Development Director

Tel. +39 346 4131428

federica.girolami@rottapharmbiotech.com